



ISHLT

A Society that Includes Basic Science, the
Failing Heart, & Advanced Lung Disease

ISHLT ABSTRACT SUBMISSION POLICIES

Approved: 17 July 2026

Definitions:

- **Authors:** All individuals listed on the abstract.
- **Submitting Author:** The individual who completes and submits the abstract.
- **Presenting Author:** The individual designated to present the abstract at the Annual Meeting.

Unless otherwise specified, submission of an abstract constitutes agreement by all Authors to comply with all policies.

ABSTRACT PREPARATION

Artificial Intelligence (AI) Disclosure: Authors must disclose any use of AI tools in the preparation of their abstract, including the name of the tool and how it was used (e.g. drafting, editing, data analysis, figure generation). Authors remain fully responsible for the accuracy, integrity, and originality of all submitted content, including content generated or modified using AI tools.

Informed Consent: Submission of an abstract signifies that all Authors certify that their study involving human subjects or tissue adheres to:

- The principles of the [Declaration of Helsinki of the World Medical Association](#)
- The [Declaration of Istanbul](#)
- The [ISHLT Statement on Transplant Ethics](#)
- Applicable institutional and national ethical requirements

Research Involving Human Organs or Tissues Procured in China

Consistent with the [Implementation Framework for the ISHLT Statement on Transplant Ethics](#)

- Research involving human organs or tissues procured in China on or before 1 January 2015 is not eligible for presentation at the ISHLT Annual Meeting.
- Research involving human organs or tissues procured in China after 1 January 2015 will be evaluated under the same reasonable confidence framework applied to all other submissions.
- 1 January 2015 marks the date on which China announced reforms and a transition to a voluntary civilian organ donation system consistent with the ethical principles reflected in the ISHLT Statement on Transplant Ethics. The use of this date as the Board's policy threshold should not be interpreted as a determination that all research conducted before that date was unethical or that all research conducted afterward is ethically compliant. Rather, it establishes a clear, objective, and consistently applied policy for ISHLT programs.

Use of Animals: Submission of an abstract signifies that all Authors agree and affirm that their study involving the use of animals complies with current NIH, EU, or analogous national guidelines for the care and use of animals.

Use of Institutional Names and Product Names:

For purposes of blind scoring, institutional names must be omitted whenever possible from the title and body of the abstract. Abstracts must use scientific or generic names when referring to products. Commercial trade names should be avoided whenever possible. If use of a trade name is necessary for clarity or identification, it should appear in brackets following the generic or scientific name. When referring to a class of similar products, the trade names of all relevant products within that class should be identified.

ABSTRACT SUBMISSION

Conflict of Interest (COI) Disclosure Requirement for the Submitting Author: The Submitting Author must submit their COI disclosure statement in accordance with the Disclosure Policy outlined below.

Abstract Revisions: Revisions to a submitted abstract can be made up until the submission deadline. After this deadline, revisions to the abstract are NOT permitted.

Permission to Publish: Submission of an abstract signifies that all Authors have given ISHLT permission for the abstract to be published in the April Abstract Supplement of the *Journal of Heart and Lung Transplantation* for distribution and/or sale by ISHLT.

Funding Disclosure: The Submitting Author must indicate if an [ACCME-defined ineligible company](#) funded the research study. If so, they must provide the name or names of the ineligible companies. The Submitting Author must also indicate if any of the co-authors are an owner or employee of an ineligible company.

Programming Decisions: ISHLT is accredited by the ACCME as a provider of Continuing Medical Education (CME) credit. The Annual Meeting Program Committee is responsible for determining what content will be included in all portions of the Scientific Program where CME is offered. Contacting any member of the Program Planning Committee to influence decision-making or inquire as to the status of a submission is strictly prohibited and may result in repercussions.

Abstract Status Notification: Following abstract submission, the person indicated as the Presenting Author will be the sole point of contact regarding the abstract submission will receive the status notification (accepted or rejected).

ABSTRACT ACCEPTANCE

Exclusivity Policy: Submission of an abstract constitutes an agreement by all Authors not to submit or present the same abstract at another scientific meeting or organization following acceptance by ISHLT. Accepted abstracts are subject to the ISHLT Embargo Policy.

Previous Publication Policy: Research based on an accepted abstract may not be presented at the ISHLT Annual Meeting if the abstract is published as an article in any journal prior to the first day of the meeting. It is the Authors' responsibility to notify ISHLT if the abstract is published as an article.

Embargo Policy: The information contained in the abstracts is embargoed until the abstracts are available online. The abstracts selected for plenary, oral, and poster presentations will be posted online in compliance with the Securities and Exchange Commission's Regulation FD. At that time, the embargo will lift on the data included in the abstract, including the abstract title, presentation time and date, and study authors. Information that goes beyond that which is contained in the abstract body (e.g., additional analysis, commentary, or updated information from those individuals and companies involved in the study) is embargoed according to the following criteria:

- For oral presentations: The embargo time is the start time of the session in which the presentation is being delivered.
- For poster presentations: The embargo lifts when the poster session containing the poster opens for viewing in the morning.

Disclosure Requirement for the Presenting Author: The Presenting Author (if not also the Submitting Author) must submit their disclosure statement *during the presentation confirmation period in January* in accordance with the Disclosure Policy outlined below.

Withdrawal Policy: Abstracts accepted for presentation can be withdrawn by the Presenting Author *during the presentation confirmation period*. The decision to withdraw should occur only in exceptional circumstances and must be made collectively by all Authors. ISHLT reserves the right to withdraw any presentation that is in violation of the Society's Abstract Submission Policies.

PRESENTATION REQUIREMENTS

Meeting Registration: The Presenting Author **must register** for the meeting and deliver the abstract presentation in person.

Permission to Record: Acceptance of an invitation to give a presentation based on a submitted abstract signifies that the Presenting Author has given permission for their presentation to be recorded in digital formats of ISHLT's choosing for distribution and/or sale by ISHLT.

Presentation of Data: A Presenting Author who accepts an invitation to give a presentation based on a submitted abstract agrees to present the data described in the abstract and may not present data not described in the abstract. A Presenting Author who presents data not described in the abstract, or declines the presentation invitation without arranging for the presentation to be given by a co-author (subject to ISHLT approval), may be sanctioned from future participation in ISHLT meetings by the Society's Board of Directors.

Fair Balance, Independent Content Validation, and Level of Evidence: All recommendations involving clinical medicine in a CME/CE activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contra-indications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Off-Label Uses and Limitations of Data: Presenting Authors must make meaningful disclosure to the attendees of a CME/CE activity when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), and disclose any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Additional Provisions: Presenting Authors must:

- attest that CME/CE activity materials will be HIPAA compliant (i.e. using de-identified patient information when possible);
- agree to obtain the necessary copyright permission(s) for any portion of the CME/CE activity materials that are not their original work or for which they do not hold the copyright;
- agree to provide meaningful opportunity for questions or scientific debate during any live presentation;
- agree to provide additional disclosure information if a financial relationship or interest is indicated.

DISCLOSURE POLICY

As an ACCME accredited provider of Continuing Medical Education (CME), the ISHLT must collect financial disclosure information from all planners, faculty, and others in control of educational content about all their financial relationships with [ACCME-defined ineligible companies](#) within the prior 24 months.

Companies that are ineligible to be accredited in the ACCME System (**ineligible companies**) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. There is no minimum financial threshold. ***Individuals must disclose regardless of their view of the relevance of the relationship to the education.*** Disclosure information must include:

- a. the name of the ineligible company with which the person has a financial relationship.
- b. the nature of the financial relationship. Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed. Research funding from ineligible companies should be

disclosed by the principal or named investigator even if that individual's institution receives the research grant and manages the funds.

It is ISHLT's responsibility to identify ***relevant financial relationships*** between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as ***relevant*** if the educational content is related to the business lines or products of the ineligible company.

ISHLT ***excludes owners or employees*** of ineligible companies from participating as planners or faculty of accredited continuing education, and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of any education carrying continuing education credit.